WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients (NeuroCovid)

November 28, 2020 updated by: University Hospital, Clermont-Ferrand

Neurological Abnormalities in SARS-CoV-2 ICU Patients. A Prospective Study. NeuroCOVID Study

The SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Unknown

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

This study is intended to investigate neurological abnormalities associated with SARS-CoV-2 infection. Complete daily neurological examinations will be routinely conducted in intensive care unit patients. Specific biological analyses will also be performed in these patients by collecting additional blood samples from an arterial or central catheter, every 2 days. These clinical and biological examinations will be continued throughout patient's stay in the intensive care unit.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized in Intensive Care Unit and infected bye SARS-CoV-2

Description

Inclusion Criteria:

  • Age ≥ 18 years old
  • COVID-19 positive patient (positive RT PCR, nasopharyngeal or tracheal)
  • Patient admitted in an intensive care unit of the department of Anesthesia, Critical Care and Perioperative of Clermont-Ferrand University Hospital
  • Patient with an arterial or central catheter to perform blood samples collection

Exclusion Criteria:

  • Patient or family member's refusal to participate
  • Neuropsychiatric history that may interfere with neurological evaluations in the intensive care unit
  • Patient not affiliated with French social security insurance
  • Patient under legal guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Dosage of biomarkers typically explored in intensive care unit delirium
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days
Plasminogen activator inhibitor-1 (PAI-1), E-selectin and angiopoietin-2
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days
Dosage of neuronal injury markers
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days
S100 β, Neuron Specific Enolase (NSE), GFAP, UCHL1, NFL
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Delirium assessment
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
CAM-ICU (Confusion Assessment Method - Intensive Care Unit) scale
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Delirium assessment
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
ICDSC (Intensive Care Delirium Screening Checklist) scale.
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Coma assessment
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
CRS-R (Coma Recovery Scale-Revised)
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Pupils characteristics
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Clinical observation
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Pupils characteristics
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Pupilometer assessment
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Neurological abnormalities
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Electroencephalogram : epileptic activity (spikes, spike-waves) or encephalopathy activity (triphasic waves))
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Neurological abnormalities
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
CT-scan
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
Neurological abnormalities
Time Frame: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days
MRI
Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 13, 2020

Primary Completion (ANTICIPATED)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 13, 2021

Study Completion (ANTICIPATED)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 13, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 16, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 24, 2020

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 25, 2020

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 1, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 28, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NeuroCovid-RNI 2020 GODET

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings